Otsuka Pharmaceutical Co. and UCB have received manufacturing and marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the antiepileptic medication E Keppra in both 250 mg and 500 mg tablets. E Keppra, originally developed by UCB as Keppra, is now marketed in more than 90 countries worldwide, including the United States. E Keppra was approved in Japan as adjunctive therapy in the treatment of partial onset seizures, with or without secondary generalization, in adult patients with epilepsy, who have not had sufficient response to other antiepileptic drugs.

Beginning in 2009, the Food and Drug Administration (FDA) began approving generic versions of Keppra, known as levetiracetam, for marketing in the United States. Generic drugs are tested by the agency to be “bioequivalent,” essentially containing the same active ingredients as the brand name drug. Once generics of Keppra were made available, many health insurance providers ordered pharmacists to switch the brand name product with a lesser expensive generic equivalent.

Formulation switching isn’t uncommon and can save both insurance companies and consumers hundreds of dollars, especially when it comes to medications for chronic conditions. In many cases, switches to generics can be made with few adverse effects.

However, epileptics can be an exception. Some experts say these patients can be more sensitive to subtle changes in inactive ingredients or in how the active ingredient is delivered.  Many patients who have had their seizures controlled with Keppra found that by switching to a generic caused their seizures to return, resulting in injuries and at least one death. 



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Generic drug savings may come at a price

Think generic medications are just the same as their brand name equivalents? Think again. Generics may...

New iPhone app helps epileptics monior seizures,...

People living with epilepsy can now keep a diary of their seizures on their iPhone, thanks to the new...

Switching from Keppra to generic can make you sick

Switching from brand name Keppra to generic Keppra (levetiracetam) to treat her epileptic seizures made...

Experimental SmartWatch offers peace of mind to...

A fully functional prototype of a wristwatch-style device that can detect myoclonic and grand mal...

Free toolkit available to parents of children...

Parents of children diagnosed with epilepsy have the daunting responsibility of helping their child...

Approval of GlaxoSmithKline, Valeant new epilepsy drug...

Despite a "thumbs-up" from a Food and Drug Administration (FDA) advisory panel on GlaxoSmithKline and...

Highly recommended

I would highly recommend this law firm to handle any of your legal needs.

—Sandy